Patients with secondary pyelonephritis have a high risk of developing chronic renal failure and a decline in the quality of life already in childhood. This pathology is prone to chronization, recurrence and progression with the formation of nephrosclerosis and the development of CRF, leading to disability of the body and requiring extraordinary interventions. Annually in the world among children it is fixed about 50 million cases of infection of urinary ways. In an open, prospective comparative study, the results of the analysis of the outcomes of the therapeutic and prophylactic efficacy of various therapies are presented in 85 children aged 4-15 years with chronic dysmetabolic pyelonephritis. Objective: to develop the principles of secondary prevention of chronic dysmetabolic pyelonephritis in children. Patients were divided into 2 groups depending on the method of treatment. 1 group consisted of 48 patients who used conventional methods of treatment. Group 2 consisted of 37 patients with children who received complex therapy: regional lymphotropic antibiotic therapy + electrophoresis with 0.5% euphillin. The results of our studies showed that after the conventional treatment there was no positive dynamics of the studied indicators of the functional state of the kidneys. A comparative assessment of the results of the study of the functional state of the kidneys and indices of endogenous intoxication showed a high efficiency of the combined use of regional lymphotropic antibiotic therapy + electrophoresis with euphyllin. Complex treatment, recommended by the authors, promotes renoprophylaxis: prevention of frequent recurrence of the disease and development of renal failure.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.